20 research outputs found

    Naturaliste plateau: constraints on the timing and evolution of the Kerguelen Large Igneous Province and its role in Gondwana breakup

    Get PDF
    Volcanism associated with the Kerguelen Large Igneous Province is found scattered in southwestern Australia (the ca 136 to ca 130 Ma Bunbury Basalts, and ca 124 Ma Wallaby Plateau), India (ca 118 Ma Rajmahal Traps and Cona Basalts), and Tibet (the ca 132 Ma Comei Basalts), but apart from the ∌70 000 km2 Wallaby Plateau, these examples are spatially and volumetrically minor. Here, we report dredge, geochronological and geochemical results from the ∌90 000 km2 Naturaliste Plateau, located ∌170 to ∌500 km southwest of Australia. Dredged lavas and intrusive rocks range from mafic to felsic compositions, and prior geophysical analyses indicate these units comprise much of the plateau substrate. 40Ar/39Ar plagioclase ages from mafic units and U–Pb zircon ages from silicic rocks indicate magmatic emplacement from 130.6 ± 1.2 to 129.4 ± 1.3 Ma for mafic rocks and 131.8 ± 3.9 to 128.2 ± 2.3 Ma for silicic rocks (2σ). These Cretaceous Naturaliste magmas incorporated a significant component of continental crust, with relatively high 87Sr/86Sr (up to 0.78), high 207Pb/204 Pb ratios (15.5–15.6), low 143Nd/144Nd (0.511–0.512) and primitive-mantle normalised Th/Nb of 11.3 and La/Nb of 3.97. These geochemical results are consistent with the plateau being underlain by continental basement, as indicated by prior interpretations of seismic and gravity data, corroborated by dredging of Mesoproterozoic granites and gneisses on the southern plateau flank. The Cretaceous Naturaliste Plateau igneous rocks have signatures indicative of extraction from a depleted mantle, with trace-element and isotopic values that overlap with Kerguelen Plateau lavas reflect crustal contamination. Our chemical and geochronological results therefore show the Naturaliste Plateau contains evidence of an extensive igneous event representing some of the earliest voluminous Kerguelen hotspot magmas. Prior work reports that contemporaneous correlative volcanic sequences underlie the nearby Mentelle Basin, and the Enderby Basin and Princess Elizabeth Trough in the Antarctic. When combined, the igneous rocks in the Naturaliste, Mentelle, Wallaby, Enderby, Princess Elizabeth, Bunbury and Comei-Cona areas form a 136–124 Ma Large Igneous Province covering >244 000 km2

    Exploring Mars at the nanoscale: applications of transmission electron microscopy and atom probe tomography in planetary exploration

    Get PDF
    The upcoming Mars Sample Return (MSR) mission aims to deliver small quantities of Martian rocks to the Earth. Investigating these precious samples requires the development and application of techniques that can extract the greatest amount of high quality data from the minimum sample volume, thereby maximising science return from MSR. Atom probe tomography (APT) and transmission electron microscopy (TEM) are two complementary techniques that can obtain nanoscale structural, geochemical and, in the case of atom probe, isotopic information from small sample volumes. Here we describe how both techniques operate, as well as review recent developments in sample preparation protocols. We also outline how APT has been successfully applied to extraterrestrial materials in the recent past. Finally, we describe how we have studied Martian meteorites using TEM and APT in close coordination in order to characterise the products of water/rock interactions in t h e cru st of Ma r s – a k ey sc ie n ce goal of MSR. Our results provide new insights into the Martian hydrosphere and the mechanisms of anhydrous-hydrous mineral replacement. In light of the unique results provided by these tools, APT and TEM should form a crucial part at the culmination of a correlative analytical pipeline for MSR mission materials

    Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

    Get PDF
    BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362
    corecore